Arthur Levin
Director/Board Member at AVIDITY BIOSCIENCES, INC.
Net worth: 7 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Troy Wilson | M | 55 | 12 years | |
| Edward Kaye | M | 75 | 7 years | |
| Sarah Boyce | F | 52 | 5 years | |
| Seth Harrison | M | 63 | 9 years | |
| Kathleen Gallagher | F | - | 3 years | |
| Adrian Krainer | M | 65 | 10 years | |
| Huw Nash | M | 57 | 10 years | |
| Eric B. Mosbrooker | M | 46 | 3 years | |
| John W. Wallen | M | 66 | 12 years | |
| Carsten Boess | M | 57 | 4 years | |
| Tamar Thompson | F | 50 | 3 years | |
| Isabel Aznarez | M | 52 | 10 years | |
| Noreen Henig | M | 59 | 5 years | |
| Arthur Tzianabos | M | 60 | 6 years | |
| Jennifer Burstein | F | 52 | 5 years | |
| Jonathan Allan | M | - | - | |
| Michael MacLean | M | 58 | 4 years | |
| Ian Smith | M | 58 | 1 years | |
| Jean Kim | F | 50 | 3 years | |
| Julie Smith | F | 53 | 4 years | |
| Garry Menzel | M | 59 | 4 years | |
| W. Flanagan | M | 62 | 3 years | |
| Joan Wood | F | - | 5 years | |
| Shamim Ruff | F | 64 | 6 years | |
| Eric Rojas | M | - | - | |
| Bo Jesper Hansen | M | 66 |
Amylon Therapeutics BV
 Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | - |
| Steven G. Hughes | M | 57 | 2 years | |
| Barry Ticho | M | 64 | 7 years | |
| Domenico Valerio | M | 67 |
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | 7 years |
| Teresa McCarthy | F | 60 | 4 years | |
| Doug Snow | M | - | 3 years | |
| Dawn Kalmar | F | 47 | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Martin | M | 50 | 5 years | |
| Robin A. Walker | M | 55 | 1 years | |
| Peter Hawryluk | M | 55 | 7 years | |
| Christopher J. Morl | M | 65 |
miRagen Therapeutics, Inc. /Old/
 miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | 3 years |
| Rod Wong | M | 47 | 2 years | |
| Todd Brady | M | 45 | 5 years | |
| Nancy M. Wyant | F | - | 5 years | |
| Steve Bajan | M | - |
Muhlenberg College
| 4 years |
| Meena | M | 51 | 4 years | |
| Charles R. Allerson | M | 56 | 2 years | |
| Gene Liau | M | 69 | 4 years | |
| Martin Brenner | M | 54 | 1 years | |
| Jae Kim | M | 54 | 1 years | |
| Andrew J. Geall | M | - | - | |
| Tony Hsu | M | - | - | |
| Aimee L. Jackson | M | - |
miRagen Therapeutics, Inc. /Old/
miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | - |
| Mitchell Eisenberg | M | - |
Muhlenberg College
| 4 years |
| Orin Levy | M | - |
Muhlenberg College
| 3 years |
| Daniel Fisher | M | 67 |
Muhlenberg College
| 4 years |
| Stephen Tulipano | M | 65 | 5 years | |
| Jeffrey Goodman | M | 68 |
Muhlenberg College
| 4 years |
| Richard A. Mitstifer | M | 66 |
Muhlenberg College
| 4 years |
| Sam Hall | M | 42 | 5 years | |
| Michael Pocalyko | M | 69 |
Muhlenberg College
| 4 years |
| Sarah G. Avery | F | - |
Muhlenberg College
| 4 years |
| Karl Bourdeau | M | - |
Muhlenberg College
| 4 years |
| Richard Frederick Brueckner | M | 74 |
Muhlenberg College
| 4 years |
| Terence S. Novak | M | 67 |
Muhlenberg College
| 4 years |
| Raymond Schilling | M | - |
Muhlenberg College
| 4 years |
| Joseph Baroldi | M | 46 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 60 | 96.77% |
| Netherlands | 2 | 3.23% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Arthur Levin
- Personal Network
